The Immuno-oncology strategy has transformed our approach to cancer treatment by delivering therapeutics which stimulate the immune response to seek out and defeat cancer. The success of these immunotherapies in some patients demonstrates the immense potential of a coordinated, effective immune response when properly targeted against cancer. In order to apply this approach in more patients, and provide protective immunity against cancer, next-generation IO approaches must engage the immune response with greater strength and precision.
The lymphatic system is the headquarters of the immune response, an interconnected series of vessels and strategically placed lymph nodes where immune cells gather to exchange information and orchestrate protective responses to threats throughout the body. Within the lymph nodes, complex immunological signals are exchanged between immune cells and collectively processed to detect disease and control the expansion, equipping, and deployment of anti-tumor immune cells.
Applying materials science to immune-biology, the Amphiphile platform is engineered to precisely and efficiently target immune-modulatory therapeutics and vaccines directly to the lymph nodes. By delivering these immunogens directly to immune cells in the lymph nodes, Amphiphiles can control immune signaling, to stimulate and orchestrate the development of the immune response against cancer. This powerful, flexible approach harnesses the full potential of the lymph nodes to transform both endogenous and engineered immune cells into potent anti-cancer therapies.